Rapid recommendation provides updated guidance on the use of adjuvant olaparib<\/p>\n<\/h3>\n
<\/b><\/p>\n
<\/b><\/p>\n
FRIDAY, July 9, 2021 (HealthDay News) — One year of adjuvant olaparib should be offered to patients with high-risk early-stage human epidermal growth factor receptor 2 (HER2)-negative breast cancer and germline BRCA<\/em> mutations after completion of (neo)adjuvant chemotherapy and local treatment, according to a rapid recommendation update published by the American Society for Clinical Oncology (ASCO).<\/p>\n Following presentation of the results from the OlympiA randomized controlled trial at the 2021 ASCO Annual Meeting and publication in the New England Journal of Medicine<\/em>, ASCO updated its recommendations for the management of hereditary breast cancer.<\/p>\n According to the updated recommendation, one year of adjuvant olaparib should be offered after completion of (neo)adjuvant chemotherapy and local treatment, including radiation, for patients with early-stage, HER2-negative breast cancer with a high risk for recurrence and germline BRCA1<\/em> or BRCA2<\/em> pathogenic or likely pathogenic variants. For patients who had surgery first, one year of adjuvant olaparib should be offered to those with triple-negative breast cancer (TNBC) and tumor size >2 cm or any involved lymph nodes. Among patients with hormone receptor-positive disease, adjuvant olaparib should be offered to those with at least four involved axillary lymph nodes. Additional recommendations for adjuvant olaparib address those with TNBC or hormone receptor-positive disease who have residual cancer.<\/p>\n “Guideline updates have traditionally required months to review new data, assemble an expert panel, develop, approve, and publish recommendations — making it difficult to provide timely support to clinicians seeking to keep abreast of rapidly advancing research,” Clifford A. Hudis, M.D., chief executive officer of ASCO, said in a statement. “ASCO’s new rapid guideline updating strategy is meant to address this need by providing rapid evidence review and dissemination of practice-changing trial results.”<\/p>\n